<DOC>
	<DOC>NCT02598622</DOC>
	<brief_summary>The purpose of this study is to see if a drug called Acetyl-L-Carnitine can help prevent painful nerve damage and nerve pain which is caused by vincristine, a drug used in chemotherapy in children being treated for newly diagnosed ALL. Acetyl-L-Carnitine is a drug available for purchase as a nutritional supplement but for the purpose of this study is experimental.</brief_summary>
	<brief_title>A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL</brief_title>
	<detailed_description />
	<mesh_term>Acetylcarnitine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Subjects must meet the following inclusion criteria. The subject must have a confirmed diagnosis of acute lymphoblastic leukemia within 1 week of starting therapy Currently being treated on a standard ALL induction regimen Subjects must be greater than or equal to 5 and less than 18 years old Signed informed consent Subjects will be excluded for the following: Preexisting neurologic disease, including grade II, III, or IV neurological status by NCI Common Toxicity Criteria v3.0 on clinical exam History of hypersensitivity to vincristine History of hypersensitivity to AcetylLcarnitine Previous use of AcetylLcarnitine Concurrent anticonvulsant use Concurrent Gabapentin use Concurrent Glutamine use Liver Function: Total bilirubin greater than 1.3 mg/dL and serum glutamicpyruvic transaminase (SGPT) (ALT) greater than 5 x upper limit of normal for age and serum albumin less than 2 g/dL Patients who are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>